Higher doses of BMS's psoriasis candidate hit Phase II efficacy mark

Bristol-Myers Squibb Co. (NYSE:BMY) said four of five doses of BMS-986165 met the primary endpoint in the Phase II IM011-011 trial to treat moderate to severe plaque psoriasis. The compound,

Read the full 302 word article

User Sign In